Información del artículo
Texto completo
Referencias no citadas
(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 130a, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270).
Recibido 29 Junio 2012
Aceptado 31 Agosto 2012
Autor para correspondencia: University of Glasgow, G12 8QQ, Reino Unido. john.mcmurray@glasgow.ac.uk
Bibliografia
[1]
Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K..
ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)..
Eur J Heart Fail. , 10 (2008), pp. 933-989
[2]
Davie AP, Francis CM, Caruana L, Sutherland GR, McMurray JJ..
Assessing diagnosis in heart failure: which features are any use?..
QJM. , 90 (1997), pp. 335-339
[3]
MantJ, DoustJ, Roalfe A, Barton R Cowie MR, Glasziou R Mant D, McManus RJ, Holder R, Deeks J, Fletcher K, Qume M, Sohanpal S, Sanders S, Hobbs FD. Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. Health Technol Assess. 2009; 13:1-207, iii..
[4]
Oudejans I, Mosterd A, Bloemen JA, Valk MJ, van Velzen E, Wielders JP, Zuithoff NP, Rutten FH, Hoes AW..
Clinical evaluation of geriatric outpatients with suspected heart failure: value of symptoms, signs, and additional tests..
Eur J Heart Fail. , 13 (2011), pp. 518-527
[5]
Fonseca C..
Diagnosis of heart failure in primary care..
Heart Fail Rev. , 11 (2006), pp. 95-107
[6]
Kelder JC, Cramer MJ, van Wijngaarden J, van Tooren R, Mosterd A, Moons KG, Lammers JW, Cowie MR, Grobbee DE, Hoes AW..
The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure..
Circulation. , 124 (2011), pp. 2865-2873
[7]
Borlaug BA, Paulus WJ..
Heart failure with preserved ejection fraction: pathophysiology diagnosis treatment..
Eur Heart J. , 32 (2011), pp. 670-679
[8]
Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, Marino P, Smiseth OA, De Keulenaer G, Leite-Moreira AF, Borbely A, Edes I, Handoko ML, Heymans S, Pezzali N, Pieske B, Dickstein K, Fraser AG, Brutsaert DL..
How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology..
Eur Heart J. , 28 (2007), pp. 2539-2550
[9]
Marwick TH, Raman SV, Carrio I, Bax JJ..
Recent developments in heart failure imaging..
JACC Cardiovasc Imaging. , 3 (2010), pp. 429-439
[10]
Paterson DI, O’Meara E, Chow BJ, Ukkonen H, Beanlands RS..
Recent advances in cardiac imaging for patients with heart failure..
Curr Opin Cardiol. , 26 (2011), pp. 132-143
[11]
McMurray JJ..
Clinical practice Systolic heart failure..
N Engl J Med. , 362 (2010), pp. 228-238
[12]
Chen J, Normand SL, Wang Y, Krumholz HM..
National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008..
JAMA. , 306 (2011), pp. 1669-1678
[13]
Dunlay SM, Redfield MM, Weston SA, Therneau TM, Hall Long K, Shah ND, Roger VL..
Hospitalizations after heart failure diagnosis a community perspective..
J Am Coll Cardiol. , 54 (2009), pp. 1695-1702
[14]
Khot UN, Jia G, Moliterno DJ, Lincoff AM, Khot MB, Harrington RA, Topol EJ..
Prognostic importance of physical examination for heart failure in non-ST-elevation acute coronary syndromes: the enduring value of Killip classification..
JAMA. , 290 (2003), pp. 2174-2181
[15]
Mosterd A, Hoes AW..
Clinical epidemiology of heart failure..
Heart. , 93 (2007), pp. 1137-1146
[16]
Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H, Camm AJ, Ellinor PT, Gollob M, Hamilton R, Hershberger RE, Judge DP, Le Marec H, McKenna WJ, Schulze-Bahr E, Semsarian C, Towbin JA, Watkins H, Wilde A, Wolpert C, Zipes DP..
HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA)..
Heart Rhythm. , 8 (2011), pp. 1308-1339
[17]
Hogg K, Swedberg K, McMurray J..
Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis..
J Am Coll Cardiol. , 43 (2004), pp. 317-327
[18]
Lam CS, Donal E, Kraigher-Krainer E, Vasan RS..
Epidemiology and clinical course of heart failure with preserved ejection fraction..
Eur J Heart Fail. , 13 (2011), pp. 18-28
[19]
Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J. doi: 10.1093/eurheartj/ehr254. Published online ahead of print 6 August 2011..
[20]
Shah AM, Mann DL..
In search of new therapeutic targets and strategies for heart failure: recent advances in basic science..
Lancet. , 378 (2011), pp. 704-712
[21]
Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJ..
More ‘malignant’ than cancer? Five-year survival following a first admission for heart failure..
Eur J Heart Fail. , 3 (2001), pp. 315-322
[22]
Stewart S, Ekman I, Ekman T, Oden A, Rosengren A..
Population impact of heart failure and the most common forms of cancer: a study of 1162 309 hospital cases in Sweden (1988 to 2004)..
Circ Cardiovasc Qual Outcomes. , 3 (2010), pp. 573-580
[23]
Jhund PS, Macintyre K, Simpson CR, Lewsey JD, Stewart S, Redpath A, Chalmers JW, Capewell S, McMurray JJ..
Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people..
Circulation. , 119 (2009), pp. 515-523
[24]
Rutten FH, Moons KG, Cramer MJ, Grobbee DE, Zuithoff NP, Lammers JW, Hoes AW..
Recognising heart failure in elderly patients with stable chronic obstructive pulmonary disease in primary care: cross sectional diagnostic study..
BMJ. , 331 (2005), pp. 1379
[25]
Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJ..
Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology..
Eur J Heart Fail. , 11 (2009), pp. 130-139
[26]
Daniels LB, Clopton P, Bhalla V, Krishnaswamy R, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA, Maisel AS..
How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Multinational Study..
Am Heart J. , 151 (2006), pp. 999-1005
[27]
Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, Solomon SD, Louie EK, Schiller NB. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr. 2010; 23:685-713; quiz 786-688..
[28]
Dokainish H, Nguyen JS, Bobek J, Goswami R, Lakkis NM..
Assessment of the American Society of Echocardiography-European Association of Echocardiography guidelines for diastolic function in patients with depressed ejection fraction: an echocardiographic and invasive haemodynamic study..
Eur J Echocardiogr. , 12 (2011), pp. 857-864
[29]
KirkpatrickJN, Vannan MA, Narula J, Lang RM..
Echocardiography in heart failure: applications, utility, and new horizons..
J Am Coll Cardiol. , 50 (2007), pp. 381-396
[30]
Lancellotti R, Moura L, Pierard LA, Agricola E, Popescu BA, Tribouilloy C, Hagendorff A, Monin JL, Badano L, Zamorano JL..
European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 2: mitral and tricuspid regurgitation (native valve disease)..
Eur J Echocardiogr. , 11 (2010), pp. 307-332
[31]
Lancellotti P, Tribouilloy C, Hagendorff A, Moura L, Popescu BA, Agricola E, Monin JL, Pierard LA, Badano L, Zamorano JL..
European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 1: aortic and pulmonary regurgitation (native valve disease)..
Eur J Echocardiogr. , 11 (2010), pp. 223-244
[32]
Popescu BA, Andrade MJ, Badano LP, Fox KF, Flachskampf FA, Lancellotti P, Varga A, Sicari R, Evangelista A, Nihoyannopoulos P, Zamorano JL, Derumeaux G, Kasprzak JD, Roelandt JR..
European Association of Echocardiography recommendations for training, competence, and quality improvement in echocardiography..
Eur J Echocardiogr. , 10 (2009), pp. 893-905
[33]
Nagueh SF, Bhatt R, Vivo RP, Krim SR, Sarvari SI, Russell K, Edvardsen T, Smiseth OA, Estep JD..
Echocardiographic evaluation of hemodynamics in patients with decompensated systolic heart failure..
Circ Cardiovasc Imaging. , 4 (2011), pp. 220-227
[34]
Sicari R, Nihoyannopoulos P, Evangelista A, Kasprzak J, Lancellotti R, Poldermans D, Voigt JU, Zamorano JL..
Stress echocardiography expert consensus statement: European Association of Echocardiography (EAE) (a registered branch of the ESC)..
Eur J Echocardiogr. , 9 (2008), pp. 415-437
[35]
Davie AP, Francis CM, Love MP, Caruana L, Starkey IR, Shaw TR, Sutherland GR, McMurray JJ..
Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction..
BMJ. , 312 (1996), pp. 222
[36]
Thomas JT, Kelly RF, Thomas SJ, Stamos TD, Albasha K, Parrillo JE, Calvin JE..
Utility of history, physical examination, electrocardiogram, and chest radiograph for differentiating normal from decreased systolic function in patients with heart failure..
Am J Med. , 112 (2002), pp. 437-445
[37]
Khunti K, Squire I, Abrams KR, Sutton AJ..
Accuracy of a 12-lead electrocardiogram in screening patients with suspected heart failure for open access echocardiography: a systematic review and meta-analysis..
Eur J Heart Fail. , 6 (2004), pp. 571-576
[38]
Madias JE..
Why recording of an electrocardiogram should be required in every inpatient and outpatient encounter of patients with heart failure..
Pacing Clin Electrophysiol. , 34 (2011), pp. 963-967
[39]
Ewald B, Ewald D, Thakkinstian A, Attia J..
Meta-analysis of B type natriuretic peptide and N-terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction..
Intern Med J. , 38 (2008), pp. 101-113
[40]
Doust JA, Glasziou PP, Pietrzak E, Dobson AJ..
A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure..
Arch Intern Med. , 164 (2004), pp. 1978-1984
[41]
Zaphiriou A, Robb S, Murray-Thomas T, Mendez G, Fox K, McDonagh T, Hardman SM, Dargie HJ, Cowie MR..
The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study..
Eur J Heart Fail. , 7 (2005), pp. 537-541
[42]
Maisel A, Mueller C, Adams K, Anker SD, Aspromonte N, Cleland JG, Cohen-Solal A, Dahlstrom U, DeMaria A, Di Somma S, Filippatos GS, Fonarow GC, Jourdain R, Komajda M, Liu PP, McDonagh T, McDonald K, Mebazaa A, Nieminen MS, Peacock WF, Tubaro M, Valle R, Vanderhyden M, Yancy CW, Zannad F, Braunwald E..
State of the art: using natriuretic peptide levels in clinical practice..
Eur J Heart Fail. , 10 (2008), pp. 824-839
[43]
Fuat A, Murphy JJ, Hungin AP, Curry J, Mehrzad AA, Hetherington A, Johnston JI, Smellie WS, Duffy V, Cawley P..
The diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure..
Br J Gen Pract. , 56 (2006), pp. 327-333
[44]
Yamamoto K, Burnett JC, Bermudez EA, Jougasaki M, Bailey KR, Redfield MM..
Clinical criteria and biochemical markers for the detection of systolic dysfunction..
J Card Fail. , 6 (2000), pp. 194-200
[45]
Cowie MR, Struthers AD, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, Sutton GC..
Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care..
Lancet. , 350 (1997), pp. 1349-1353
[46]
Krishnaswamy P, Lubien E, Clopton P, Koon J, Kazanegra R, Wanner E, Gardetto N, Garcia A, DeMaria A, Maisel AS..
Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction..
AmJ Med. , 111 (2001), pp. 274-279
[47]
Kelder JC, Cowie MR, McDonagh TA, Hardman SM, Grobbee DE, Cost B, Hoes AW..
Quantifying the added value of BNP in suspected heart failure in general practice: an individual patient data meta-analysis..
Heart. , 97 (2011), pp. 959-963
[48]
Kelder JC, Cramer MJ, Verweij WM, Grobbee DE, Hoes AW..
Clinical utility of three B-type natriuretic peptide assays for the initial diagnostic assessment of new slow-onset heart failure..
J Card Fail. , 17 (2011), pp. 729-734
[49]
Gustafsson F, Steensgaard-Hansen F, BadskjaerJ, Poulsen AH, Corell R, Hildebrandt P..
Diagnostic and prognostic performance of N-terminal proBNP in primary care patients with suspected heart failure..
J Card Fail. , 11 (2005), pp. S15-S20
[50]
Nielsen OW, Rasmussen V, Christensen NJ, Hansen JF..
Neuroendocrine testing in community patients with heart disease: plasma N-terminal proatrial natriuretic peptide predicts morbidity and mortality stronger than catecholamines and heart rate variability..
Scand J Clin Lab Invest. , 64 (2004), pp. 619-628
[51]
Maisel A, Mueller C, Nowak R, Peacock WF, Landsberg JW, Ponikowski P, Mockel M, Hogan C, Wu AH, Richards M, Clopton R, Filippatos GS, Di Somma S, Anand I, Ng L, Daniels LB, Neath SX, Christenson R, Potocki M, McCord J, Terracciano G, Kremastinos D, Hartmann O, von Haehling S, Bergmann A, Morgenthaler NG, Anker SD..
Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial..
J Am Coll Cardiol. , 55 (2010), pp. 2062-2076
[52]
Schwitter J..
Extending the frontiers of cardiac magnetic resonance..
Circulation. , 118 (2008), pp. 109-112
[53]
Gebker R, Schwitter J, Fleck E, Nagel E..
How we perform myocardial perfusion with cardiovascular magnetic resonance..
J Cardiovasc Magn Reson. , 9 (2007), pp. 539-547
[54]
Beller GA, Heede RC..
SPECT imaging for detecting coronary artery disease and determining prognosis by noninvasive assessment of myocardial perfusion and myocardial viability..
J Cardiovasc Transl Res. , 4 (2011), pp. 416-424
[55]
Leong DP, De Pasquale CG, Selvanayagam JB..
Heart failure with normal ejection fraction: the complementary roles of echocardiography and CMR imaging..
JACC Cardiovasc Imaging. , 3 (2010), pp. 409-420
[56]
Myerson SG. Valvular and hemodynamic assessment with CMR. Heart Fail Clin. 2009; 5:389-400, vi-vii..
[57]
Raman SV, Simonetti OP. The CMR examination in heart failure. Heart Fail Clin. 2009; 5:283-300, v..
[58]
Sheikine Y, Di Carli MF..
Integrated PET/CT in the assessment of etiology and viability in ischemic heart failure..
Curr Heart Fail Rep. , 5 (2008), pp. 136-142
[59]
Miller JM, Rochitte CE, Dewey M, Arbab-Zadeh A, Niinuma H, Gottlieb I, Paul N, Clouse ME, Shapiro EP, Hoe J, Lardo AC, Bush DE, de Roos A, Cox C, Brinker J, Lima JA..
Diagnostic performance of coronary angiography by 64-row CT..
N Engl J Med. , 359 (2008), pp. 2324-2336
[60]
Beanlands RS, Nichol G, Huszti E, Humen D, Racine N, Freeman M, Gulenchyn KY, Garrard L, deKemp R, Guo A, Ruddy TD, Benard F, Lamy A, Iwanochko RM..
F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2)..
J Am Coll Cardiol. , 50 (2007), pp. 2002-2012
[61]
Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, ShanewiseJ, Solomon S, Spencer KT, St John Sutton M, Stewart W..
Recommendations for chamber quantification..
Eur J Echocardiogr. , 7 (2006), pp. 79-108
[62]
Lang RM, Badano LP, Tsang W, Adams DH, Agricola E, Buck T, Faletra FF, Franke A, HungJ, de Isla LP, Kamp O, KasprzakJD, Lancellotti R, MarwickTH, McCulloch ML, Monaghan MJ, Nihoyannopoulos P, Pandian NG, Pellikka PA, Pepi M, Roberson DA, Shernan SK, Shirali GS, Sugeng L, Ten Cate FJ, Vannan MA, Zamorano JL, Zoghbi WA..
EAE/ASE Recommendations for Image Acquisition and Display Using Three-Dimensional Echocardiography..
Eur Heart J Cardiovasc Imaging. , 13 (2012), pp. 1-46
[63]
Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka PA, Evangelisa A..
Recommendations for the evaluation of left ventricular diastolic function by echocardiography..
Eur J Echocardiogr. , 10 (2009), pp. 165-193
[64]
Nagueh SF, Middleton KJ, Kopelen HA, Zoghbi WA, Quinones MA..
Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures..
J Am Coll Cardiol. , 30 (1997), pp. 1527-1533
[65]
Schwitter J, Arai AE..
Assessment of cardiac ischaemia and viability: role of cardiovascular magnetic resonance..
Eur Heart J. , 32 (2011), pp. 799-809
[66]
Kilner PJ, Geva T, Kaemmerer H, Trindade PT, Schwitter J, Webb GD..
Recommendations for cardiovascular magnetic resonance in adults with congenital heart disease from the respective working groups of the European Society of Cardiology..
Eur Heart J. , 31 (2010), pp. 794-805
[67]
Luchinger R, Schwitter J, Bruder O. Safety of CMR. En: Schwitter J, ed. CMR Update 2012. 2nd ed. Lausanne; p. 31-51. ISBN: 978-3-033-01674-3..
[68]
Bruder O, Schneider S, Nothnagel D, Pilz G, Lombardi M, Sinha A, Wagner A, Dill T, Frank H, van Rossum A, Schwitter J, Nagel E, Senges J, Sabin G, Sechtem U, Mahrholdt H..
Acute adverse reactions to gadolinium-based contrast agents in CMR: multicenter experience with 17,767 patients. from the EuroCMR Registry..
J Am Coll Cardiol-Cardiovasc Imaging. , 4 (2011), pp. 1171-1176
[69]
Sheikine Y, Di Carli MF..
Integrated PET/CT in the assessment of etiology and viability in ischemic heart failure..
Curr Heart Fail Rep. , 5 (2008), pp. 136-142
[70]
Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van’ t Veer M, Klauss V, Manoharan G, Engstrom T, Oldroyd KG, Ver Lee PN, MacCarthy PA, Fearon WF..
Fractional flow reserve versus angiography for guiding percutaneous coronary intervention..
N Engl J Med. , 360 (2009), pp. 213-224
[71]
Wijns W, Kolh R, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, Huber K, James S, KnuutiJ, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, Pirlet C, PomarJL, Reifart N, Ribichini FL, Schalij MJ, Sergeant P, Serruys PW, SilberS, Sousa Uva M, Taggart D..
Guidelines on myocardial revascularization..
Eur Heart J. , 31 (2010), pp. 2501-2555
[72]
Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, Levine GN, Narula J, Starling RC, Towbin J, Virmani R..
The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology..
Eur Heart J. , 28 (2007), pp. 3076-3093
[73]
Arena R, MyersJ, Guazzi M..
Cardiopulmonary exercise testing is a core assessment for patients with heart failure..
Congest Heart Fail. , 17 (2011), pp. 115-119
[74]
Wedel H, McMurrayJJ, Lindberg M, WikstrandJ, ClelandJG, CornelJH, Dunselman R, Hjalmarson A, Kjekshus J, Komajda M, Kuusi T, Vanhaecke J, Waagstein F..
Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide..
Eur J Heart Fail. , 11 (2009), pp. 281-291
[75]
Allen LA, Felker GM, Pocock S, McMurray JJ, Pfeffer MA, Swedberg K, Wang D, Yusuf S, Michelson EL, Granger CB..
Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program..
Eur J Heart Fail. , 11 (2009), pp. 170-177
[76]
Jackson CE, Solomon SD, Gerstein HC, Zetterstrand S, Olofsson B, Michelson EL, Granger CB, Swedberg K, Pfeffer MA, Yusuf S, McMurray JJ..
Albuminuria in chronic heart failure: prevalence and prognostic importance..
Lancet. , 374 (2009), pp. 543-550
[77]
Felker GM, Allen LA, Pocock SJ, Shaw LK, McMurray JJ, Pfeffer MA, Swedberg K, Wang D, Yusuf S, Michelson EL, Granger CB..
Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank..
J Am Coll Cardiol. , 50 (2007), pp. 40-47
[78]
Pocock SJ, Wang D, Pfeffer MA, Yusuf S, McMurray JJ, Swedberg KB, Ostergren J, Michelson EL, Pieper KS, Granger CB..
Predictors of mortality and morbidity in patients with chronic heart failure..
Eur Heart J. , 27 (2006), pp. 65-75
[79]
Komajda M, Carson PE, Hetzel S, McKelvie R, McMurray J, Ptaszynska A, Zile MR, Demets D, Massie BM..
Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE)..
Circ Heart Fail. , 4 (2011), pp. 27-35
[80]
Ketchum ES, Levy WC..
Establishing prognosis in heart failure: a multimarker approach..
Prog Cardiovasc Dis. , 54 (2011), pp. 86-96
[81]
Stewart S, Jenkins A, Buchan S, McGuire A, Capewell S, McMurray JJ..
The current cost of heart failure to the National Health Service in the UK..
Eur J Heart Fail. , 4 (2002), pp. 361-371
[82]
Masson S, Latini R, Anand IS, Barlera S, Angelici L, Vago T, Tognoni G, Cohn JN..
Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial)..
J Am Coll Cardiol. , 52 (2008), pp. 997-1003
[83]
Wong M, Staszewsky L, Latini R, Barlera S, Volpi A, Chiang YT, Benza RL, Gottlieb SO, Kleemann TD, Rosconi F, Vandervoort PM, Cohn JN..
Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study..
J Am Coll Cardiol. , 40 (2002), pp. 970-975
[84]
Ekman I, Cleland JG, Andersson B, Swedberg K..
Exploring symptoms in chronic heart failure..
Eur J Heart Fail. , 7 (2005), pp. 699-703
[85]
Packer M, Narahara KA, Elkayam U, Sullivan JM, Pearle DL, Massie BM, Creager MA..
Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal Investigators of the REFLECT Study..
J Am Coll Cardiol. , 22 (1993), pp. 65-72
[86]
Cowley AJ, Stainer K, Wynne RD, Rowley JM, Hampton JR..
Comparison of the effects of captopril and enoximone in patients with severe heart failure: a placebo controlled double-blind study..
Int J Cardiol. , 24 (1989), pp. 311-316
[87]
Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med. 1987;316:1429-35..
[88]
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med. 1991;325:293-302..
[89]
Garg R, Yusuf S..
Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials..
JAMA. , 273 (1995), pp. 1450-1456
[90]
Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Ryden L, Thygesen K, Uretsky BF..
Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group..
Circulation. , 100 (1999), pp. 2312-2318
[91]
The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685-691..
[92]
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9-13..
[93]
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999; 353:2001-7..
[94]
Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, Wikstrand J, El Allaf D, Vitovec J, Aldershvile J, Halinen M, Dietz R, Neuhaus KL, Janosi A, Thorgeirsson G, Dunselman PH, Gullestad L, Kuch J, Herlitz J, Rickenbacher P, Ball S, Gottlieb S, Deedwania P..
Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group..
JAMA. , 283 (2000), pp. 1295-1302
[95]
Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi R, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL..
Effect of carvedilol on survival in severe chronic heart failure..
N Engl J Med. , 344 (2001), pp. 1651-1658
[96]
Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL..
Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study..
Circulation. , 106 (2002), pp. 2194-2199
[97]
Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, Bohm M, Anker SD, Thompson SG, Poole-Wilson PA..
Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)..
Eur Heart J. , 26 (2005), pp. 215-225
[98]
Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH..
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U. S. Carvedilol Heart Failure Study Group..
N Engl J Med. , 334 (1996), pp. 1349-1355
[99]
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J..
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators..
N Engl J Med. , 341 (1999), pp. 709-717
[100]
Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B..
Eplerenone in patients with systolic heart failure and mild symptoms..
N Engl J Med. , 364 (2011), pp. 11-21
[101]
Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, Torp-Pedersen C, Ball S, Pogue J, Moye L, Braunwald E..
Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group..
Lancet. , 355 (2000), pp. 1575-1581
[102]
McMurray J, Cohen-Solal A, Dietz R, Eichhorn E, Erhardt L, Hobbs FD, Krum H, Maggioni A, McKelvie RS, Pina IL, Soler-Soler J, Swedberg K..
Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice..
Eur J Heart Fail. , 7 (2005), pp. 710-721
[103]
Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001; 344:1659-67..
[104]
Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene A..
Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial..
Lancet. , 362 (2003), pp. 7-13
[105]
Krum H, Roecker EB, Mohacsi P, Rouleau JL, Tendera M, Coats AJ, Katus HA, Fowler MB, Packer M..
Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study..
JAMA. , 289 (2003), pp. 712-718
[106]
Jondeau G, Neuder Y, Eicher JC, Jourdain P, Fauveau E, Galinier M, Jegou A, Bauer F, Trochu JN, Bouzamondo A, Tanguy ML, Lechat P..
B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode..
Eur Heart J. , 30 (2009), pp. 2186-2192
[107]
Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, KleimanJ, Gatlin M..
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction..
N Engl J. Med. , 348 (2003), pp. 1309-1321
[108]
Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K..
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial..
Lancet. , 362 (2003), pp. 772-776
[109]
Maggioni AP, Anand I, Gottlieb SO, Latini R, Tognoni G, Cohn JN..
Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors..
J Am Coll Cardiol. , 40 (2002), pp. 1414-1421
[110]
Cohn JN, Tognoni G..
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure..
N Engl J Med. , 345 (2001), pp. 1667-1675
[111]
McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA..
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial..
Lancet. , 362 (2003), pp. 767-771
[112]
Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L..
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study..
Lancet. , 376 (2010), pp. 875-885
[113]
The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med. 1997;336:525-33..
[114]
Cohn JN, Archibald DG, Ziesche S, FranciosaJA, Harston WE, Tristani FE, Dunkman WB, JacobsW, Francis GS, Flohr KH..
for the Veterans Administration Cooperative Study Group. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study..
N EnglJ Med. , 314 (1986), pp. 1547-1552
[115]
Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, Bhat G, Goldman S, Fletcher RD, Doherty J, Hughes CV, Carson R, Cintron G, Shabetai R, Haakenson C..
A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure..
N EnglJ Med. , 325 (1991), pp. 303-310
[116]
Taylor AL, Ziesche S, Yancy C, Carson P, D’Agostino R, Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel M, Cohn JN..
Combination of isosorbide dinitrate and hydralazine in blacks with heart failure..
N EnglJ Med. , 351 (2004), pp. 2049-2057
[117]
Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G..
Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, doubleblind, placebo-controlled trial..
Lancet. , 372 (2008), pp. 1223-1230
[118]
Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B..
Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II..
Lancet. , 355 (2000), pp. 1582-1587
[119]
Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, Riegger GA, Malbecq W, Smith RD, Guptha S, Poole-Wilson PA..
Effects of highdose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial..
Lancet. , 374 (2009), pp. 1840-1848
[120]
Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM..
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both..
N EnglJ Med. , 349 (2003), pp. 1893-1906
[121]
Dickstein K, Kjekshus J..
Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan..
Lancet. , 360 (2002), pp. 752-760
[122]
Fox K, Ford I, Steg PG, Tendera M, Ferrari R..
Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial..
Lancet. , 372 (2008), pp. 807-816
[123]
Hood WBJr, Dans AL, Guyatt GH, Jaeschke R, McMurray JJ..
Digitalis for treatment of congestive heart failure in patients in sinus rhythm: a systematic review and meta-analysis..
J Card Fail. , 10 (2004), pp. 155-164
[124]
Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet. 1999;354:447-55..
[125]
Rauch B, Schiele R, SchneiderS, Diller F, Victor N, Gohlke H, Gottwik M, Steinbeck G, Del Castillo U, Sack R, Worth H, Katus H, Spitzer W, Sabin G, Senges J..
OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction..
Circulation. , 122 (2010), pp. 2152-2159
[126]
Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington R, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D, Bax J, Vahanian A, Auricchio A, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Filippatos G, Funck-Brentano C, Hasdai D, Hoes A, Kearney R, Knuuti J, Kolh R, McDonagh T, Moulin C, Poldermans D, Popescu BA, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vardas P, Widimsky P, Windecker S, Berkenboom G, De Graaf J, Descamps O, Gotcheva N, Griffith K, Guida GF, Gulec S, Henkin Y, Huber K, Kesaniemi YA, Lekakis J, Manolis AJ, Marques-Vidal P, Masana L, McMurray J, Mendes M, Pagava Z, Pedersen T, Prescott E, Rato Q, Rosano G, Sans S, Stalenhoef A, Tokgozoglu L, Viigimaa M, Wittekoek ME, Zamorano JL..
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)..
Eur Heart J. , 32 (2011), pp. 1769-1818
[127]
Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JG, Cornel JH, Dunselman R, Fonseca C, Goudev A, Grande R, Gullestad L, Hjalmarson A, Hradec J, Janosi A, Kamensky G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J..
Rosuvastatin in older patients with systolic heart failure..
N Engl J Med. , 357 (2007), pp. 2248-2261
[128]
Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G..
Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebocontrolled trial..
Lancet. , 372 (2008), pp. 1231-1239
[129]
Krum H, Massie B, Abraham WT, Dickstein K, Kober L, McMurray JJ, Desai A, Gimpelewicz C, Kandra A, Reimund B, Rattunde H, Armbrecht J..
Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study..
EurJ Heart Fail. , 13 (2011), pp. 107-114
[130]
Gheorghiade M, Albaghdadi M, Zannad F, Fonarow GC, Bohm M, Gimpelewicz C, Botha J, Moores S, Lewis EF, Rattunde H, Maggioni A..
Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT)..
EurJ Heart Fail. , 13 (2011), pp. 100-106
[131]
Homma S, Thompson JL, Pullicino PM, Levin B, Freudenberger RS, Teerlink JR, Ammon SE, Graham S, Sacco RL, Mann DL, Mohr JP, Massie BM, Labovitz AJ, Anker SD, Lok DJ, Ponikowski R Estol CJ, Lip GY, Di Tullio MR, Sanford AR, Mejia V, Gabriel AP, Del Valle ML, Buchsbaum R; the WARCEF Investigators. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med 2012; Published online ahead of print 2 May 2012. PubMed PMID: 22551105..
[132]
Komajda M, McMurray JJ, Beck-Nielsen H, Gomis R, Hanefeld M, Pocock SJ, Curtis PS, Jones NP, Home PD..
Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial..
Eur Heart J. , 31 (2010), pp. 824-831
[133]
Hernandez AV, Usmani A, Rajamanickam A, Moheet A..
Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized 153. clinical trials..
AmJ Cardiovasc Drugs. , 11 (2011), pp. 115-128
[134]
Erdmann E, Charbonnel B, Wilcox RG, Skene AM, Massi-Benedetti M, Yates J, Tan M, Spanheimer R, Standl E, Dormandy JA..
Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from 154. the PROactive study (PROactive 08)..
Diabetes Care. , 30 (2007), pp. 2773-2778
[135]
Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S..
Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem 155. Postinfarction Research Group..
Circulation. , 83 (1991), pp. 52-60
[136]
Mamdani M, Juurlink DN, Lee DS, Rochon PA, Kopp A, Naglie G, Austin PC, Laupacis A, Stukel TA..
Cyclo-oxygenase-2 inhibitors versus non-selective 156. nonsteroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study..
Lancet. , 363 (2004), pp. 1751-1756
[137]
Huerta C, Varas-Lorenzo C, Castellsague J, Garcia Rodriguez LA..
Non-steroidal anti-inflammatory drugs and risk of first hospital admission for heart failure in 157. the general population..
Heart. , 92 (2006), pp. 1610-1615
[138]
Setaro JF, Zaret BL, Schulman DS, Black HR, Soufer R..
Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling 158. and normal left ventricular systolic performance..
AmJ Cardiol. , 66 (1990), pp. 981-986
[139]
Hung MJ, Cherng WJ, Kuo LT, Wang CH..
Effect of verapamil in elderly patients with left ventricular diastolic dysfunction as a cause of congestive heart failure..
Int J Clin Pract. , 56 (2002), pp. 57-62
[140]
Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J..
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved 159..
Trial. Lancet. , 362 (2003), pp. 777-781
[141]
Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J..
The perindopril in elderly people with chronic heart failure (PEP-CHF) study..
Eur 160. Heart J. , 27 (2006), pp. 2338-2345
[142]
Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A..
Irbesartan in patients with heart failure and preserved ejection fraction..
N Engl J Med. , 359 (2008), pp. 2456-2467
[143]
Chung MK, Szymkiewicz SJ, Shao M, Zishiri E, Niebauer MJ, Lindsay BD, Tchou PJ..
Aggregate national experience with the wearable cardioverterdefibrillator: event rates, compliance, and survival..
J Am Coll Cardiol. , 56 (2010), pp. 194-203
[145]
A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med. 1997;337:1576-83. 166..
[146]
Kuck KH, Cappato R, SiebelsJ, Ruppel R..
Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH)..
Circulation. , 102 (2000), pp. 748-754
[147]
Connolly SJ, Gent M, Roberts RS, Dorian R, Roy D, Sheldon RS, Mitchell LB, Green MS, Klein GJ, O’Brien B..
Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against 167. amiodarone..
Circulation. , 101 (2000), pp. 1297-1302
[148]
Oseroff O, Retyk E, Bochoeyer A..
Subanalyses of secondary prevention implantable cardioverter-defibrillatortrials: antiarrhythmics versus implantable defibrillators 168. (AVID). Canadian Implantable Defibrillator Study (CIDS), and Cardiac Arrest Study Hamburg (CASH)..
Curr Opin Cardiol. , 19 (2004), pp. 26-30
[149]
Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, Levine JH, Saksena 169, Waldo S, Wilber AL, Brown D, Heo MWM..
Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. 170..
N Engl J Med. , 335 (1996), pp. 1933-1940
[150]
Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH..
Amiodarone or an implantable 171. cardioverter-defibrillator for congestive heart failure..
N Engl J Med. , 352 (2005), pp. 225-237
[151]
Hohnloser SH, Kuck KH, Dorian R, Roberts RS, Hampton JR, Hatala R, Fain E, Gent M, Connolly SJ..
Prophylactic use of an implantable cardioverterdefibrillator after acute myocardial infarction..
N EnglJ Med. , 351 (2004), pp. 2481-2488
[152]
Steinbeck G, Andresen D, Seidl K, Brachmann J, Hoffmann E, Wojciechowski D, Kornacewicz-Jach Z, Sredniawa B, Lupkovics G, Hofgartner F, Lubinski A, Rosenqvist M, Habets A, Wegscheider K, SengesJ. Defibrillator implantation early 173. after myocardial infarction. N Engl J Med. 2009;361:1427-36..
[153]
Kadish A, Dyer A, Daubert JP, Quigg R, Estes NA, Anderson KP, Calkins H, Hoch D, Goldberger J, Shalaby A, Sanders WE, Schaechter A, Levine JH..
Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy..
N EnglJ Med. , 350 (2004), pp. 2151-2158
[154]
Stewart GC, Weintraub JR, Pratibhu PP, Semigran MJ, Camuso JM, Brooks K, Tsang SW, Anello MS, Nguyen VT, Lewis EF, Nohria A, Desai AS, Givertz MM, Stevenson LW..
Patient expectations from implantable defibrillators to prevent death in heart failure..
J Card Fail. , 16 (2010), pp. 106-113
[155]
Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NA, 3rd, Foster E, Greenberg H, Higgins SL, Pfeffer MA, Solomon SD, Wilber D, Zareba W..
Cardiac-resynchronization therapy for the prevention of heart-failure events..
N EnglJ Med. , 361 (2009), pp. 1329-1338
[156]
Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, Hohnloser SH, Nichol G, Birnie DH, SappJL, Yee R, Healey JS, Rouleau JL..
Cardiac-resynchronization therapy for mild-to-moderate heart failure..
N EnglJ Med. , 363 (2010), pp. 2385-2395
[157]
Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson R, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM..
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure..
N EnglJ Med. , 350 (2004), pp. 2140-2150
[158]
Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L..
The effect of cardiac resynchronization on morbidity and mortality in heart failure..
N Engl J Med. , 352 (2005), pp. 1539-1549
[159]
Dickstein K, Vardas PE, Auricchio A, Daubert JC, Linde C, McMurray J, Ponikowski R Priori SG, Sutton R, van Veldhuisen DJ. 2010 focused update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC Guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. EurJ Heart Fail. 2010;12:1143-53..
[160]
Beshai JF, Grimm RA, Nagueh SF, Baker JH, 2nd Beau SL, Greenberg SM, Pires LA, Tchou PJ..
Cardiac-resynchronization therapy in heart failure with narrow QRS complexes..
N EnglJ Med. , 357 (2007), pp. 2461-2471
[161]
Chung ES, Leon AR, Tavazzi L, Sun JP, Nihoyannopoulos R, Merlino J, Abraham WT, Ghio S, Leclercq C, Bax JJ, Yu CM, Gorcsan J, St John Sutton M, De Sutter J, Murillo J..
Results of the Predictors of Response to CRT (PROSPECT) trial..
Circulation. , 117 (2008), pp. 2608-2616
[162]
Linde C, Abraham WT, Gold MR, St John Sutton M, Ghio S, Daubert C..
Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms..
J Am Coll Cardiol. , 52 (2008), pp. 1834-1843
[163]
Leclercq C, Walker S, Linde C, Clementy J, Marshall AJ, Ritter R, Djiane R, Mabo R, Levy T, Gadler F, Bailleul C, Daubert JC..
Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation..
Eur Heart J. , 23 (2002), pp. 1780-1787
[164]
Wilton SB, Leung AA, Ghali WA, Faris R, Exner DV..
Outcomes of cardiac resynchronization therapy in patients with versus those without atrial fibrillation: a systematic review and meta-analysis..
Heart Rhythm. , 8 (2011), pp. 1088-1094
[165]
Tops LF, Schalij MJ, Bax JJ..
The effects of right ventricular apical pacing on ventricular function and dyssynchrony implications for therapy..
J Am Coll Cardiol. , 54 (2009), pp. 764-776
[166]
Vardas PE, Auricchio A, Blanc JJ, Daubert JC, Drexler H, Ector H, Gasparini M, Linde C, Morgado FB, Oto A, Sutton R, Trusz-Gluza M..
Guidelines for cardiac pacing and cardiac resynchronization therapy: the Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in collaboration with the European Heart Rhythm Association..
Eur Heart J. , 28 (2007), pp. 2256-2295
[167]
Camm AJ, Kirchhof R, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna R, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh R, Le Heuzey JY, Ponikowski R, Rutten FH..
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)..
Eur HeartJ. , 31 (2010), pp. 2369-2429
[168]
Lewis RV, McMurray J, McDevitt DG..
Effects of atenolol, verapamil, and xamoterol on heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation..
J Cardiovasc Pharmacol. , 13 (1989), pp. 1-6
[169]
Khand AU, Rankin AC, Martin W, Taylor J, Gemmell I, Cleland JG..
Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure?..
J Am Coll Cardiol. , 42 (2003), pp. 1944-1951
[170]
Lewis RV, Laing E, Moreland TA, Service E, McDevitt DG..
A comparison of digoxin, diltiazem and their combination in the treatment of atrial fibrillation..
Eur Heart J. , 9 (1988), pp. 279-283
[171]
Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, Hillege HL, Bergsma-KadijkJA, Cornel JH, Kamp O, Tukkie R, Bosker HA, Van Veldhuisen DJ, Van den Berg MP..
Lenient versus strict rate control in patients with atrial fibrillation..
N EnglJ Med. , 362 (2010), pp. 1363-1373
[172]
Roy D, Talajic M, Nattel S, Wyse DG, Dorian R, Lee KL, Bourassa MG, Arnold JM, Buxton AE, Camm AJ, Connolly SJ, Dubuc M, Ducharme A, Guerra PG, Hohnloser SH, Lambert J, Le Heuzey JY, O’Hara G, Pedersen OD, Rouleau JL, Singh BN, Stevenson LW, Stevenson WG, Thibault B, Waldo AL..
Rhythm control versus rate control for atrial fibrillation and heart failure..
N EnglJ Med. , 358 (2008), pp. 2667-2677
[173]
Piepoli M, Villani GQ, Ponikowski R, Wright A, Flather MD, Coats AJ..
Overview and meta-analysis of randomised trials of amiodarone in chronic heart failure..
Int J Cardiol. , 66 (1998), pp. 1-10
[174]
Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators. Lancet 1997;350:1417-24..
[175]
Khan MN, Jais P, Cummings J, Di Biase L, Sanders P, Martin DO, Kautzner J, H ao S, 192. Themistoclakis S, Fanelli R, Potenza D, Massaro R, Wazni O, Schweikert R, Saliba. W, Wang R Al-Ahmad A, Beheiry S, Santarelli P, Starling RC, Dello Russo A, Pelargonio G, Brachmann J, Schibgilla V, Bonso A, Casella M, R aviele A, 193. Haissaguerre M, Natale A. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N EnglJ Med 2008;359: 1778-85..
[176]
MacDonald MR, Connelly DT, Hawkins NM, Steedman T, Payne J, Shaw M, Denvir M, Bhagra S, Small S, Martin W, McMurray JJ, Petrie MC..
Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: a randomised controlled trial..
Heart. , 97 (2011), pp. 740-747
[177]
Kober L, Torp-Pedersen C, McMurray JJ, Gotzsche O, Levy S, Crijns H, Amlie J, Carlsen J..
Increased mortality after dronedarone therapy for severe heart failure..
N EnglJ Med. , 358 (2008), pp. 2678-2687
[178]
Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, Atar D, Avezum 195. A, Blomstrom P, Borggrefe M, Budaj A, Chen SA, Ching CK, Commerford P, Dans A, Davy JM, Delacretaz E, Di Pasquale G, Diaz R, Dorian P, Flaker G, Golitsyn S, Gonzalez-Hermosillo A, Granger CB, Heidbuchel H, Kautzner J, Kim JS, Lanas F, Lewis BS, Merino JL, Morillo C, Murin J, Narasimhan C, Paolasso E, Parkhomenko A, Peters NS, Sim KH, Stiles MK, Tanomsup S, Toivonen L, Tomcsanyi J, Torp- 196. Pedersen C, Tse HF, Vardas R Vinereanu D, Xavier D, Zhu J, Zhu JR, Baret-Cormel L, Weinling E, Staiger C, Yusuf S, Chrolavicius S, Afzal R, Hohnloser SH. Dronedarone in highrisk permanent atrial fibrillation. N Engl J Med 2011;365:2268-76..
[179]
Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg 197. D, Baker A, Friedman L, Greene HL, Huther ML, Richardson DW, the CAST Investigators. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781-8..
[180]
Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ..
Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation..
Chest. , 137 (2010), pp. 263-272
[181]
Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY..
A novel userfriendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial 198. fibrillation: the Euro Heart Survey..
Chest. , 138 (2010), pp. 1093-1100
[182]
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L..
Dabigatran versus warfarin in patients with atrial fibrillation..
N EnglJ Med. , 361 (2009), pp. 1139-1151
[183]
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P,Jansky P, Lewis BS, Lopez-SendonJL, Pais R Parkhomenko 200. A, Verheugt FW, Zhu J, Wallentin L. Apixaban versus warfarin in patients with atrial fibrillation. N EnglJ Med 2011; 365:981-92..
[184]
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, F ox KA, 201. Califf RM. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N EnglJ Med 2011;365:883-91..
[185]
Hart RG, Benavente O, McBride R, Pearce LA..
Antithrombotic therapy to prevent 202. stroke in patients with atrial fibrillation: a meta-analysis..
Ann Intern Med. , 131 (1999), pp. 492-501
[186]
Larson RJ, Fisher ES. Should aspirin be continued in patients started on warfarin? J Gen Intern Med 2004;19:879-86. 203..
[187]
Aliot EM, Stevenson WG, Almendral-Garrote JM, Bogun F, Calkins CH, Delacretaz E, Bella PD, Hindricks G, Jais P, Josephson ME, Kautzner J, Kay GN, Kuck KH, Lerman BB, Marchlinski F, Reddy V, Schalij MJ, Schilling R, Soejima K, Wilber D. EHRA/HRS Expert Consensus on Catheter Ablation of Ventricular Arrhythmias: 204. developed in a partnership with the European Heart Rhythm Association (EHRA), a Registered Branch of the European Society of Cardiology (ESC), and the Heart Rhythm Society (HRS); in collaboration with the American College of Cardiology (ACC) and the American Heart Association (AHA). Europace 2009;11:771-17..
[188]
McMurray JJ, Anand IS, Diaz R, Maggioni AP, O’Connor C, Pfeffer MA, P olu KR, 205. Solomon SD, Sun Y, Swedberg K, Tendera M, van Veldhuisen DJ, Wasserman SM, Young JB. Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a phase III, anaemia correction, morbiditymortality trial. Eur J Heart Fail 2009;11:795-801..
[189]
Packer M, O’Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller AB, Neuberg GW, Frid D, Wertheimer JH, Cropp AB, DeMets DL..
Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group..
N Engl J Med. , 335 (1996), pp. 1107-1114
[190]
Wijeysundera HC, Hansen MS, Stanton E, Cropp AS, Hall C, Dhalla NS, Ghali J, Rouleau JL..
Neurohormones and oxidative stress in nonischemic cardiomyopathy: relationship to survival and the effect of treatment with amlodipine..
Am Heart J. , 146 (2003), pp. 291-297
[191]
Yusuf S, Zucker D, Peduzzi R, Fisher LD, Takaro T, Kennedy JW, Davis K, Killip T, Passamani E, Norris R, Mathur V, Varnauskas E, Chalmers TC..
Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from 206. randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration..
Lancet. , 344 (1994), pp. 563-570
[192]
Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, Ali IS, Pohost G, Gradinac S, Abraham WT, Yii M, Prabhakaran D, Szwed H, Ferrazzi P, P etrie MC, 207. O’Connor CM, Panchavinnin P, She L, Bonow RO, Rankin GR, Jones RH, RouleauJL. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N EnglJ Med 2011;364:1607-16..
[193]
Akashi YJ, Springer J, Anker SD..
Cachexia in chronic heart failure: prognostic implications and novel therapeutic approaches..
Curr Heart Fail Rep. , 2 (2005), pp. 198-203
[194]
Eschenhagen T, Force T, Ewer MS, de Keulenaer GW, Suter TM, Anker SD, Avkiran M, de Azambuja E, Balligand JL, Brutsaert DL, Condorelli G, Hansen A, Heymans S, Hill JA, Hirsch E, Hilfiker-Kleiner D, Janssens S, de Jong S, Neubauer G, Pieske B, Ponikowski P, Pirmohamed M, Rauchhaus M, Sawyer D, Sugden PH, Wojta J, Zannad F, Shah AM..
Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology..
Eur J Heart Fail. , 13 (2011), pp. 1-10
[195]
Jones AL, Barlow M, Barrett-Lee PJ, Canney PA, Gilmour IM, Robb SD, Plummer CJ, Wardley AM, Verrill MW..
Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring..
Br J Cancer. , 100 (2009), pp. 684-692
[196]
Dungen HD, Apostolovic S, Inkrot S, Tahirovic E, Topper A, Mehrhof F, Prettin C, Putnikovic B, Neskovic AN, Krotin M, Sakac D, Lainscak M, Edelmann F, Wachter R, Rau T, Eschenhagen T, Doehner W, Anker SD, Waagstein F, Herrmann-Lingen C, Gelbrich G, Dietz R..
Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial..
Eur J Heart Fail. , 13 (2011), pp. 670-680
[197]
O’Connor CM, Jiang W, Kuchibhatla M, Silva SG, Cuffe MS, Callwood DD, Zakhary B, Stough WG, Arias RM, Rivelli SK, Krishnan R..
Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial..
J Am Coll Cardiol. , 56 (2010), pp. 692-699
[198]
McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania R, Diem R, Einhorn D, Fonseca V, Fulcher GR, Gaciong Z, Gaztambide S, Giles T, Horton E, Ilkova H, Jenssen T, Kahn SE, Krum H, Laakso M, Leiter LA, Levitt NS, Mareev V, Martinez F, Masson C, Mazzone T, Meaney E, Nesto R, Pan C, Prager R, Raptis SA, Rutten GE, Sandstroem H, Schaper F, Scheen A, Schmitz O, Sinay I, Soska V, Stender S, Tamas G, Tognoni G, Tuomilehto J, Villamil AS, Vozar J, Califf RM..
Effect of valsartan on the incidence of diabetes and cardiovascular events..
N EnglJ Med. , 362 (2010), pp. 1477-1490
[199]
Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, Raskin R, Wright JT, Oakes R, Lukas MA, Anderson KM, Bell DSH..
for the GEMINI Investigators. Metabolic Effects of carvedilol vs metoprolol in patients with type4 2 diabetes mellitus and hypertension—a randomized contolled trial..
JAMA. , 292 (2004), pp. 2227-2236
[200]
MacDonald MR, Eurich DT, Majumdar SR, Lewsey JD, Bhagra S, Jhund PS, Petrie MC, McMurray JJ, Petrie JR, McAlister FA..
Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research Database..
Diabetes Care. , 33 (2010), pp. 1213-1218
[201]
Guazzi M, Vicenzi M, Arena R, Guazzi MD..
PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study..
Circ Heart Fail. , 4 (2011), pp. 8-17
[202]
Hare JM, Mangal B, Brown J, Fisher C, Freudenberger R, Colucci WS, Mann DL, Liu R, Givertz MM, Schwarz RP..
Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study..
J Am Coll Cardiol. , 51 (2008), pp. 2301-2309
[203]
Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 2000;283:1967-75..
[204]
Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, Wiltse C, Wright TJ..
Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON)..
Eur J Heart Fail. , 5 (2003), pp. 659-667
[205]
Cohn JN, Ziesche S, Smith R, Anand I, Dunkman WB, Loeb H, Cintron G, Boden W, Baruch L, Rochin P, Loss L..
Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group..
Circulation. , 96 (1997), pp. 856-863
[207]
Dorszewski A, Gohmann E, Dorszewski B, Werner GS, Kreuzer H, Figulla HR..
Vasodilation by urapidil in the treatment of chronic congestive heart failure in addition to angiotensin-converting enzyme inhibitors is not beneficial: results of a placebo-controlled, double-blind study..
J Card Fail. , 3 (1997), pp. 91-96
[208]
Bayliss J, Norell MS, Canepa-Anson R, Reid C, Poole-Wilson P, Sutton G..
Clinical importance of the renin-angiotensin system in chronic heart failure: double blind comparison of captopril and prazosin..
Br Med J (Clin Res Ed). , 290 (1985), pp. 1861-1865
[209]
Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Luscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P..
Ferric carboxymaltose in patients with heart failure and iron deficiency..
N Engl J Med. , 361 (2009), pp. 2436-2448
[210]
Ronco C, McCullough P, Anker SD, Anand I, Aspromonte N, Bagshaw SM, Bellomo R, Berl T, Bobek I, Cruz DN, Daliento L, Davenport A, Haapio M, Hillege H, House AA, Katz N, Maisel A, Mankad S, Zanco R, Mebazaa A, Palazzuoli A, Ronco F, Shaw A, Sheinfeld G, Soni S, Vescovo G, Zamperetti N, Ponikowski P..
Acute Dialysis Quality Initiative (ADQI) consensus Group. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative..
Eur Heart J. , 31 (2010), pp. 703-711
[211]
Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian R Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syva’nne M, Scholte Op, Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) *Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2012, doi: 10.1093/eurheartj/ehs092. Published online ahead of print 3 May 2012..
[212]
McKelvie RS, Moe GW, Cheung A, Costigan J, Ducharme A, Estrella-Holder E, Ezekowitz JA, Floras J, Giannetti N, Grzeslo A, Harkness K, Heckman GA, Howlett JG, Kouz S, Leblanc K, Mann E, O’Meara E, Rajda M, Rao V, Simon J, Swiggum E, Zieroth S, Arnold JM, Ashton T, D’Astous M, Dorian R, Haddad H, Isaac DL, Leblanc MH, Liu R, Sussex B, Ross HJ..
The 2011 Canadian Cardiovascular Society heart failure management guidelines update: focus on sleep apnea, renal dysfunction, mechanical circulatory support, and palliative care..
Can J Cardiol. , 27 (2011), pp. 319-338
[213]
Kasai T, Bradley TD..
Obstructive sleep apnea and heart failure: pathophysiologic and therapeutic implications..
J Am Coll Cardiol. , 57 (2011), pp. 119-127
[214]
Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, LeWinter MM, Deswal A, Rouleau JL, Ofili EO, Anstrom KJ, Hernandez AF, McNulty SE, Velazquez EJ, Kfoury AG, Chen HH, Givertz MM, Semigran MJ, Bart BA, Mascette AM, Braunwald E, O’Connor CM..
Diuretic strategies in patients with acute decompensated heart failure..
N EnglJ Med. , 364 (2011), pp. 797-805
[215]
Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Olsson CG, Turpie AG..
Prevention of venous thromboembolism in medical patients with enoxaparin: a subGroup analysis of the MEDENOX study..
Blood Coagul Fibrinolysis. , 14 (2003), pp. 341-346
[216]
Kleber FX, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach CW..
Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease..
Am Heart J. , 145 (2003), pp. 614-621
[217]
Tebbe U, Schellong SM, Haas S, Gerlach HE, Abletshauser C, Sieder C, Bramlage R, Riess H..
Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure: a subGroup analysis of the randomized, controlled CERTIFY study..
Am Heart J. , 161 (2011), pp. 322-328
[218]
Gray A, Goodacre S, Newby DE, Masson M, Sampson F, Nicholl J..
Noninvasive ventilation in acute cardiogenic pulmonary edema..
N Engl J Med. , 359 (2008), pp. 142-151
[219]
Cotter G, Metzkor E, Kaluski E, Faigenberg Z, Miller R, Simovitz A, Shaham O, Marghitay D, Koren M, Blatt A, Moshkovitz Y, Zaidenstein R, Golik A..
Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema..
Lancet. , 351 (1998), pp. 389-393
[220]
Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002;287:1531-40..
[221]
Cohn JN, Franciosa JA, Francis GS, Archibald D, Tristani F, Fletcher R, Montero A, Cintron G, Clarke J, Hager D, Saunders R, Cobb F, Smith R, Loeb H, Settle H..
Effect of short-term infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure: results of a Veterans Administration cooperative study..
N Engl J Med. , 306 (1982), pp. 1129-1135
[222]
Mehta SR, Cannon CP, Fox KA, Wallentin L, Boden WE, Spacek R, Widimsky R, McCullough PA, Hunt D, Braunwald E, Yusuf S..
Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials..
JAMA. , 293 (2005), pp. 2908-2917
[223]
Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group. Lancet 1994;343:311-22..
[224]
Dargie HJ..
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial..
Lancet. , 357 (2001), pp. 1385-1390
[225]
Park JH, Balmain S, Berry C, Morton JJ, McMurray JJ..
Potentially detrimental cardiovascular effects of oxygen in patients with chronic left ventricular systolic dysfunction..
Heart. , 96 (2010), pp. 533-538
[226]
Rosenberg J, Gustafsson F, Galatius S, Hildebrandt PR..
Combination therapy with metolazone and loop diuretics in outpatients with refractory heart failure: an observational study and review of the literature..
Cardiovasc Drugs Ther. , 19 (2005), pp. 301-306
[227]
Channer KS, McLean KA, Lawson-Matthew R, Richardson M..
Combination diuretic treatment in severe heart failure: a randomised controlled trial..
Br Heart J. , 71 (1994), pp. 146-150
[228]
Tan LB, Bryant S, Murray RG..
Detrimental haemodynamic effects of cyclizine in heart failure..
Lancet. , 1 (1988), pp. 560-561
[229]
O’Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, Heizer GM, Komajda M, Massie BM, McMurray JJ, Nieminen MS, Reist CJ, Rouleau JL, Swedberg K, Adams KF Jr, Anker SD, Atar D, Battler A, Botero R, Bohidar NR, Butler J, Clausell N, Corbalan R, Costanzo MR, Dahlstrom U, Deckelbaum LI, Diaz R, Dunlap ME, Ezekowitz JA, Feldman D, Felker GM, Fonarow GC, Gennevois D, Gottlieb SS, Hill JA, Hollander JE, Howlett JG, Hudson MP, Kociol RD, Krum H, Laucevicius A, Levy WC, Mendez GF, Metra M, Mittal S, Oh BH, Pereira NL, Ponikowski R Tang WH, Tanomsup S, Teerlink JR, Triposkiadis F, Troughton RW, Voors AA, Whellan DJ, Zannad F, Califf RM. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011;365:32-43..
[230]
van de Borne R, Oren R, Somers VK..
Dopamine depresses minute ventilation in patients with heart failure..
Circulation. , 98 (1998), pp. 126-131
[231]
Gheorghiade M, Konstam MA, Burnett JC, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C..
Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials..
JAMA. , 297 (2007), pp. 1332-1343
[232]
Sjauw KD, Engstrom AE, Vis MM, van der Schaaf RJ, Baan J, Koch KT, de Winter RJ, Piek JJ, Tijssen JG, Henriques JP..
A systematic review and meta-analysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines?..
Eur Heart J. , 30 (2009), pp. 459-468
[233]
Costanzo MR, Saltzberg MT, Jessup M, Teerlink JR, Sobotka PA..
Ultrafiltration is associated with fewer rehospitalizations than continuous diuretic infusion in patients with decompensated heart failure: results from UNLOAD..
J Card Fail. , 16 (2010), pp. 277-284
[234]
Shah MR, Hasselblad V, Stevenson LW, Binanay C, O’Connor CM, Sopko G, Califf RM..
Impact of the pulmonary artery catheter in critically ill patients: meta-analysis of randomized clinical trials..
JAMA. , 294 (2005), pp. 1664-1670
[235]
Shepperd S, McClaran J, Phillips CO, Lannin NA, Clemson LM, McCluskey A, Cameron ID, Barras SL. Discharge planning from hospital to home. Cochrane Database Syst Rev 2010;(1):CD000313..
[236]
Phillips CO, Wright SM, Kern DE, Singa RM, Shepperd S, Rubin HR..
Comprehensive discharge planning with postdischarge support for older patients with congestive heart failure: a meta-analysis..
JAMA. , 291 (2004), pp. 1358-1367
[237]
McDonagh TA, Blue L, Clark AL, Dahlstrom U, Ekman I, Lainscak M, McDonald K, Ryder M, Stromberg A, Jaarsma T..
European Society of Cardiology Heart Failure Association Standards for delivering heart failure care..
Eur J Heart Fail. , 13 (2011), pp. 235-241
[238]
Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso R, Dudek D, Gielen S, Huber K, Ohman M, Petrie MC, Sonntag F, Uva MS, Storey RF, Wijns W, Zahger D, Bax JJ, Auricchio A, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Knuuti J, Kolh R, McDonagh T, Moulin C, Poldermans D, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Torbicki A, Vahanian A, Windecker S, Achenbach S, Badimon L, Bertrand M, Botker HE, Collet JP, Crea F, Danchin N, Falk E, Goudevenos J, Gulba D, Hambrecht R, Herrmann J, Kastrati A, Kjeldsen K, Kristensen SD, Lancellotti R, Mehilli J, Merkely B, Montalescot G, Neumann FJ, Neyses L, PerkJ, Roffi M, Romeo F, Ruda M, Swahn E, Valgimigli M, Vrints CJ, Widimsky P..
ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)..
Eur Heart J. , 32 (2011), pp. 2999-3054
[239]
Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, Filippatos G, Fox K, Huber K, Kastrati A, Rosengren A, Steg PG, Tubaro M, Verheugt F, Weidinger F, Weis M..
Committee for Practice Guidelines (CPG). Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology..
Eur Heart J. , 29 (2008), pp. 2909-2945
[240]
Torbicki A, Perrier A, Konstantinides S, Agnelli G, Galie N, Pruszczyk R, Bengel F, Brady AJ, Ferreira D, Janssens U, Klepetko W, Mayer E, Remy-Jardin M, Bassand JP..
Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC)..
Eur HeartJ. , 29 (2008), pp. 2276-2315
[241]
Galie N, Hoeper MM, Humbert M, Torbicki A, VachieryJL, Barbera JA, Beghetti M, Corris R, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G..
Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)..
Eur Heart J. , 30 (2009), pp. 2493-2537
[242]
Mebazaa A, Pitsis AA, Rudiger A, TollerW, Longrois D, Ricksten SE, Bobek I, De Hert S, Wieselthaler G, Schirmer U, von Segesser LK, Sander M, Poldermans D, Ranucci M, Karpati PC, Wouters R, Seeberger M, Schmid ER, Weder W, Follath F..
Clinical review: practical recommendations on the management of perioperative heart failure in cardiac surgery..
Crit Care. , 14 (2010), pp. 201
[243]
Sliwa K, Hilfiker-Kleiner D, Petrie MC, Mebazaa A, Pieske B, Buchmann E, Regitz-Zagrosek V, Schaufelberger M, Tavazzi L, van Veldhuisen DJ, Watkins H, Shah AJ, Seferovic PM, Elkayam U, Pankuweit S, Papp Z, Mouquet F, McMurray JJ..
Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy..
EurJ Heart Fail. , 12 (2010), pp. 767-778
[245]
Diller GP, Dimopoulos K, Okonko D, Li W, Babu-Narayan SV, Broberg CS, Johansson B, Bouzas B, Mullen MJ, Poole-Wilson PA, Francis DP, Gatzoulis MA..
Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implication..
Circulation. , 112 (2005), pp. 828-835
[246]
Baumgartner H, Bonhoeffer R, De Groot NM, de Haan F, Deanfield JE, Galie N, Gatzoulis MA, Gohlke-Baerwolf C, Kaemmerer H, Kilner R, Meijboom F, Mulder BJ, Oechslin E, Oliver JM, Serraf A, Szatmari A, Thaulow E, Vouhe PR, Walma E..
ESC Guidelines for the management of grown-up congenital heart disease (new version 2010)..
Eur Heart J. , 31 (2010), pp. 2915-2957
[247]
Jones RH, Velazquez EJ, Michler RE, Sopko G, Oh JK, O’Connor CM, Hill JA, Menicanti L, Sadowski Z, Desvigne-Nickens P, Rouleau JL, Lee KL..
Coronary bypass surgery with or without surgical ventricular reconstruction..
N Engl J Med. , 360 (2009), pp. 1705-1717
[248]
Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baro’ n-Esquivias G, Baumgartner H, Borger MA, Carrel TP, De Bonis M, Evangelista A, Falk V, Iung B, Lancellotti R Pierard L, Price S, Schaefers H-J, Schuler G, Stepinska J, Swedberg K, Takkenberg J, Von Oppell UO, Windecker S, Zamorano JL, Zembala M. Guidelines on the Management of Valvular Heart Disease (Version 2012). The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur HeartJ 2012, doi:10.1093/eurheartj/ehs109. in press..
[249]
Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Williams M, Dewey T, Kapadia S, Babaliaros V, Thourani VH, Corso P, Pichard AD, Bavaria JE, Herrmann HC, Akin JJ, Anderson WN, Wang D, Pocock SJ..
Transcatheter versus surgical aorticvalve replacement in high-risk patients..
N EnglJ Med. , 364 (2011), pp. 2187-2198
[250]
Smith CR, Leon MB, Mack MJ, Miller C, Moses JW, Svensson LG, Tuzcu M, Webb JG, Fontana GP, Makkar RR, WIlliams M, Dewey T, Kapadia S, Babaliaros V, Thourani VH, Corso P, Pichard AD, Bavaria JE, Herrmann HC, Akin J, Anderson WN, Wang D, Pocock SJ..
for the PARTNER Trial Investigators. Transcatheter versus surgical aortic-valve replacement in high-risk patients..
N Eng J Med. , 364 (2011), pp. 2187-2198
[251]
Feldman T, Kar S, Rinaldi M, Fail R, Hermiller J, Smalling R, Whitlow PL, Gray W, Low R, Herrmann HC, Lim S, Foster E, Glower D..
Percutaneous mitral repair with the MitraClip system: safety and midterm durability in the initial EVEREST (Endovascular Valve Edge-to-Edge REpair Study) cohort..
J Am Coll Cardiol. , 54 (2009), pp. 686-694
[252]
Banner NR, Bonser RS, Clark AL, Clark S, Cowburn PJ, Gardner RS, Kalra PR, McDonagh T, Rogers CA, Swan L, Parameshwar J, Thomas HL, Williams SG..
UK guidelines for referral and assessment of adults for heart transplantation..
Heart. , 97 (2011), pp. 1520-1527
[253]
Mehra MR, Kobashigawa J, Starling R, Russell S, Uber PA, Parameshwar J, Mohacsi R, Augustine S, Aaronson K, Barr M..
Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates-2006..
J Heart Lung Transplant. , 25 (2006), pp. 1024-1042
[254]
Shah KB, Tang DG, Cooke RH, Harton S, Flattery M, Katlaps GJ, Kasirajan V, Hess ML..
Implantable mechanical circulatory support: demystifying patients with ventricular assist devices and artificial hearts..
Clin Cardiol. , 34 (2011), pp. 147-152
[255]
Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, Long JW, Ascheim DD, Tierney AR, Levitan RG, Watson JT, Meier P, Ronan NS, Shapiro PA, Lazar RM, Miller LW, Gupta L, Frazier OH, Desvigne-Nickens P, Oz MC, Poirier VL..
Long-term use of a left ventricular assist device for end-stage heart failure..
N EnglJ Med. , 345 (2001), pp. 1435-1443
[256]
Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, Sun B, Tatooles AJ, Delgado RM, Long JW, Wozniak TC, Ghumman W, Farrar DJ, Frazier OH..
Advanced heart failure treated with continuous-flow left ventricular assist device..
N EnglJ Med. , 361 (2009), pp. 2241-2251
[257]
Birks EJ, Tansley PD, Hardy J, George RS, Bowles CT, Burke M, Banner NR, Khaghani A, Yacoub MH..
Left ventricular assist device and drug therapy for the reversal of heart failure..
N EnglJ Med. , 355 (2006), pp. 1873-1884
[258]
Khazanie P, Rogers JG..
Patient selection for left ventricular assist devices..
Congest Heart Fail. , 17 (2011), pp. 227-234
[259]
Pagani FD, Miller LW, Russell SD, Aaronson KD, John R, Boyle AJ, Conte JV, Bogaev RC, MacGillivray TE, Naka Y, Mancini D, Massey HT, Chen L, Klodell CT, Aranda JM, Moazami N, Ewald GA, Farrar DJ, Frazier OH..
Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device..
J Am Coll Cardiol. , 54 (2009), pp. 312-321
[260]
Lainscak M, Blue L, Clark AL, Dahlstrom U, Dickstein K, Ekman I, McDonagh T, McMurrayJJ, Ryder M, Stewart S, Stromberg A, Jaarsma T..
Self-care management of heart failure: practical recommendations from the Patient Care Committee of the Heart Failure Association of the European Society of Cardiology..
Eur J Heart Fail. , 13 (2011), pp. 115-126
[261]
Paterna S, Gaspare R, Fasullo S, Sarullo FM, Di Pasquale P..
Normal-sodium diet compared with low-sodium diet in compensated congestive heart failure: is sodium an old enemy or a new friend?..
Clin Sci (Lond). , 114 (2008), pp. 221-230
[262]
Powell LH, Calvin JE, Richardson D, Janssen I, Mendes de Leon CF, Flynn KJ, Grady KL, Rucker-Whitaker CS, Eaton C, Avery E..
Self-management counseling in patients with heart failure: the heart failure adherence and retention randomized behavioral trial..
JAMA. , 304 (2010), pp. 1331-1338
[263]
O’Connor CM, Whellan DJ, Lee KL, Keteyian SJ, Cooper LS, Ellis SJ, Leifer ES, Kraus WE, Kitzman DW, Blumenthal JA, Rendall DS, Miller NH, Fleg JL, Schulman KA, McKelvie RS, Zannad F, Piña IL..
HF-ACTION Investigators. Efficacy and safety of exercise training in patients with chronic heart failure: HFACTION randomized controlled trial..
JAMA. , 301 (2009), pp. 1439-1450
[264]
Piepoli MF, Conraads V, Corra U, Dickstein K, Francis DP, Jaarsma T, McMurray J, Pieske B, Piotrowicz E, Schmid JP, Anker SD, Solal AC, Filippatos GS, Hoes AW, Gielen S, Giannuzzi P, Ponikowski PP..
Exercise training in heart failure: from theory to practice. A consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation..
Eur J Heart Fail. , 13 (2011), pp. 347-357
[265]
Sochalski J, Jaarsma T, Krumholz HM, Laramee A, McMurray JJ, Naylor MD, Rich MW, Riegel B, Stewart S..
What works in chronic care management: the case of heart failure..
Health Aff. , 28 (2009), pp. 179-189
[266]
Porapakkham P, Zimmet H, Billah B, Krum H..
B-type natriuretic peptide-guided heart failure therapy: a meta-analysis..
Arch Intern Med. , 170 (2010), pp. 507-514
[267]
van Veldhuisen DJ, Braunschweig F, Conraads V, Ford I, Cowie MR, Jondeau G, Kautzner J, Aguilera RM, Lunati M, Gerritse B, Borggrefe M..
Intrathoracic impedance monitoring, audible patient alerts, and outcome in patients with heart failure..
Circulation. , 124 (2011), pp. 1719-1726
[268]
Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, Strickland W, Neelagaru S, Raval N, Krueger S, Weiner S, Shavelle D, Jeffries B, Yadav JS..
Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial..
Lancet. , 377 (2011), pp. 658-666
[269]
Anker SD, Koehler F, Abraham WT..
Telemedicine and remote management of patients with heart failure..
Lancet. , 378 (2011), pp. 731-739
[270]
Inglis SC, Clark RA, McAlister FA, Stewart S, Cleland JG..
Which components of heart failure programmes are effective?. A systematic review and meta-analysis of the outcomes of structured telephone support or telemonitoring as the primary component of chronic heart failure management in 8323 patients: Abridged Cochrane Review..
Eur J Heart Fail. , 13 (2011), pp. 1028-1040
[271]
Jaarsma T, Beattie JM, Ryder M, Rutten FH, McDonagh T, Mohacsi R, Murray SA, Grodzicki T, Bergh I, Metra M, Ekman I, Angermann C, Leventhal M, Pitsis A, Anker SD, Gavazzi A, Ponikowski R, Dickstein K, Delacretaz E, Blue L, Strasser F, McMurray J..
Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology..
EurJ Heart Fail. , 11 (2009), pp. 433-443
